Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Breast implant-associated anaplastic large cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
The absolute risk is small and the exposure is very common, so the right advice to a woman who already has textured implants and no symptoms is a question about communication rather than about oncology; current guidance is not to remove them.
Why a textured surface and not a smooth one is not fully explained, and the proposed mechanisms, chronic inflammation and an allergic response to the surface, have not been shown to be the cause.
Because the disease is almost always cured by surgery, there are no randomised trials and there will not be, so the management of the minority with invasive disease rests on case series.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
A seroma appearing around a breast implant more than a year after the operation is aspirated and the fluid sent for cytology and for CD30 immunohistochemistry, rather than simply drained. That single step is what makes the diagnosis, and draining without testing is how it is missed. The same applies to a new mass in the capsule or to capsular contracture appearing years after surgery. Imaging, usually ultrasound in the first instance, maps the fluid and any mass.
WHO-HAEM5 lists it as one of the three anaplastic large cell lymphomas, describes it as usually non-invasive and associated with an excellent outcome, and records that invasion of adjacent structures worsens the outlook.
The Dutch pathology registry found an implant on the same side in 32 of 43 women with breast anaplastic large cell lymphoma against 1 of 146 with other primary breast lymphomas, and put the cumulative risk in women with implants at 29 per million by age 50 and 82 per million by 70.
The revised fourth edition of the WHO classification named breast implant-associated anaplastic large cell lymphoma as a provisional entity separate from systemic ALK-negative disease.